tiprankstipranks
Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure
PremiumCompany AnnouncementsViracta Therapeutics Explores Strategic Options After NAVAL-1 Closure
2M ago
Viracta Therapeutics announces exploration of strategic alternatives
Premium
The Fly
Viracta Therapeutics announces exploration of strategic alternatives
2M ago
Viracta Therapeutics Highlights Strategic Focus and Financials
Premium
Company Announcements
Viracta Therapeutics Highlights Strategic Focus and Financials
3M ago
VIRX Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsVIRX Upcoming Earnings Report: What to Expect?
4M ago
Viracta Therapeutics downgraded to Market Perform from Outperform at Leerink
Premium
The Fly
Viracta Therapeutics downgraded to Market Perform from Outperform at Leerink
6M ago
Viracta Therapeutics price target lowered to $4 from $6 at RBC Capital
Premium
The Fly
Viracta Therapeutics price target lowered to $4 from $6 at RBC Capital
6M ago
Xoma receives $8.1M milestone related to Day One’s sale of PRV
PremiumThe FlyXoma receives $8.1M milestone related to Day One’s sale of PRV
9M ago
Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M
Premium
The Fly
Day One Biopharmaceuticals announces sale of Priority Review Voucher for $108M
9M ago
Viracta Therapeutics price target lowered to $11 from $13 at Oppenheimer
Premium
The Fly
Viracta Therapeutics price target lowered to $11 from $13 at Oppenheimer
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100